CLINICAL_TRIALS ClinicalTrials.gov record update

A Two-Part, Phase II, Multi-center Study of the ERK Inhibitor Ulixertinib (BVD-523) for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT04488003
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:26:29.003805+00:00
Published At: 2024-06-04T00:00:00+00:00
Record Updated At: 2024-06-04
Results Posted At: 2024-06-04
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Advanced Solid Tumor", "BRAF Gene Mutation", "BRAF Gene Alteration", "MEK Mutation", "MEK Alteration", "MAP2K1 Gene Mutation", "MAP2K1 Gene Alteration", "MAP2K2 Gene Mutation", "MAP2K2 Gene Alteration"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2024-06-04"
protocolSection.identificationModule.nctId: "NCT04488003"
protocolSection.identificationModule.officialTitle: "A Two-Part, Phase II, Multi-center Study of the ERK Inhibitor Ulixertinib (BVD-523) for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2024-06-04"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.